Sign in to view content

Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study

Priya Sharma Vakharia, MD

Video
Published 2023

Related

Mitochondria-Targeted Drug Elamipretide for Treatment of Vision Loss in Dry AMD With Noncentral Geographic Atrophy
Scott W. Cousins, MD
Annual Meeting Talks
2019
Development of a Novel Retinal Tamponade Agent to Replace Fluorinated Gas and Silicone Oil
James A Stefater, MD, PhD
Annual Meeting Talks
2019
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more